<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN" "http://www.w3.org/TR/REC-html40/loose.dtd">
<html><body><html><body><section class="summaryOfFindings"><div class="section-header section-collapse-header" id="CD003220-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"><div class="section-header" id="CD003220-sec-0029"></div> <div class="table" id="CD003220-tbl-0001"> <a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading">
<span class="table-label">Summary of findings for the main comparison.</span>Â <span class="table-title">Pulpotomy compared with pulpotomy using alternative medicament/technique for extensive decay in primary teeth</span>
</div>
<table class="summary-of-findings framed">
<tbody>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Pulpotomy compared with pulpotomy using alternative medicament/technique for extensive decay in primary teeth</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Population:</b> children with extensive decay in primary teeth </p> <p><b>Settings:</b> primary care </p> <p><b>Intervention:</b> pulpotomy with one type of medicament </p> <p><b>Comparison:</b> pulpotomy using alternative medicament or different technique </p> </td> </tr>
<tr class="table-header separated">
<td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Outcomes</b> </p> </td> <td align="" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Relative effect<br> (95% CI)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Number of participants<br> (studies)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Quality of the evidence<br> (GRADE)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Comments</b> </p> </td> </tr>
<tr class="table-header separated">
<td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Assumed risk</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Corresponding risk</b> </p> </td> </tr>
<tr class="table-header separated">
<td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Control</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Experimental</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>MTA versus formocresol</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Clinical failure</b> </p> <p><b>(12 months)</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>28 per 1000</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>8.6 per 1000 (2.8 per 1000 to 26.0 per 1000)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>RR 0.31 (0.10 to 0.93)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>740</p> <p>(12 studies)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br><b>moderate</b><sup>1</sup></p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Failure rate less than 3% across both the MTA and formocresol treatment groups. Seven of the 12 studies had no failures at 12 months. </p> <p>No evidence of a difference in clinical failure at 6 months or 24 months</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Radiological failure</b> </p> <p><b>(12 months)</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>50 per 1000</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>20.5 per 1000 (9.5 per 1000 to 44.5 per 1000)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>RR 0.41 (0.19 to 0.89)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>740 (12 studies)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br><b>moderate</b><sup>1</sup></p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Failure rate 5% across formocresol treatment groups and 2.1% across MTA treatment groups. Five of the 12 studies had no failures at 12 months. </p> <p>Results similar at 6 and 24 months</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>MTA versus calcium hydroxide</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Clinical failure (12 months)</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>14 per 1000</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>2.2 per 1000 (0.02 per 1000 to 9.8 per 1000)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>RR 0.16 (0.04 to 0.70)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>150 (4 studies)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br><b>moderate</b><sup>1</sup></p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Results similar at 24 months.</p> <p>No evidence of a difference in clinical failure at 6 months</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Radiological failure</b> </p> <p><b>(12 months)</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>351 per 1000</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>42.1 per 1000 (14 per 1000 to 126.4 per 1000)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>RR 0.12 (0.04 to 0.36)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>150 (4 studies)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br><b>low</b><sup>2</sup></p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Results similar at 6 and 24 months</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Calcium hydroxide versus formocresol</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Clinical failure (12 months)</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>115 per 1000</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>215 per 1000 (140.3 per 1000 to 332.4 per 1000)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>RR 1.87 (1.22 to 2.89)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>332 (6 studies)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br><b>moderate</b><sup>1</sup></p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Results similar at 6 months</p> <p>No evidence of a difference in clinical failure at 24 months</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Radiological failure (12 months)</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>253 per 1000</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>470.6 per 1000 (359.3 per 1000 to 617.3 per 1000)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>RR 1.86 (1.42 to 2.44)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>332 (6 studies)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br><b>moderate</b><sup>1</sup></p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Results similar at 6 and 24 months</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Other comparisons assessed in more than one trial that had treatment failures</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Clinical failure (at six, 12 and 24 months)</b> </p> </td> <td align="" valign="" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>The quality of the evidence was<b>low</b> for 4 comparisons<sup>3</sup>: laser versus ferric sulphate; Biodentine versus MTA; ferric sulphate versus formocresol; electrosurgery versus ferric sulphate; calcium hydroxide versus ferric sulphate. </p> <p>The quality of the evidence was <b>very low</b> for 5 comparisons: NaOCl versus ferric sulphate<sup>4</sup>; laser versus electrosurgery<sup>4</sup>; MTA versus ferric sulphate<sup>5</sup>; ABS versus ferric sulphate<sup>6</sup>; EMD versus formocresol<sup>7</sup>. </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Radiological failure (at six, 12 and 24 months)</b> </p> </td> <td align="" valign="" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>The quality of the evidence was<b>low</b> for 8 comparisons: NaOCl versus ferric sulphate<sup>2</sup>; MTA versus ferric sulphate<sup>3</sup>; Biodentine versus MTA<sup>3</sup>; ferric sulphate versus formocresol<sup>3</sup>; laser versus ferric sulphate<sup>3</sup>; electrosurgery versus ferric sulphate<sup>3</sup>; ABS versus ferric sulphate<sup>3</sup>; laser versus electrosurgery<sup>3</sup>; calcium hydroxide versus ferric sulphate (favouring ferric sulphate)<sup>3</sup>. </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>GRADE Working Group grades of evidence<br><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr>
</tbody>
<tfoot><tr>
<td colspan="7"> <div class="table-footnote"> <p><sup>1.</sup> Downgraded 1 level due to high risk of bias<br><sup>2.</sup> Downgraded 1 level due to high risk of bias and 1 level due to substantial inconsistency<br><sup>3.</sup> Downgraded 1 level due to high risk of bias and 1 level due to imprecision<br><sup>4.</sup> Downgraded 1 level due to high risk of bias and 2 levels due to imprecision<br><sup>5.</sup> Downgraded 1 level due to high risk of bias, 1 level due to moderate inconsistency and 1 level due to imprecision<br><sup>6.</sup> Downgraded 1 level due to high risk of bias and 2 levels due to very serious imprecision<br><sup>7.</sup> Downgraded 1 level due to high risk of bias, 1 level due to substantial inconsistency and 1 level due to imprecision </p> </div> </td> </tr></tfoot>
</table>
</div> <div class="table" id="CD003220-tbl-0002"> <a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading">
<span class="table-label">Summary of findings 2.</span>Â <span class="table-title">Pulpectomy compared with pulpectomy using alternative medicament for extensive decay in primary teeth</span>
</div>
<table class="summary-of-findings framed">
<tbody>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Pulpectomy compared with pulpectomy using alternative medicament for extensive decay in primary teeth</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Population:</b> children with extensive decay in primary teeth </p> <p><b>Settings:</b> primary care </p> <p><b>Intervention:</b> pulpectomy with 1 type of medicament </p> <p><b>Comparison:</b> pulpectomy using alternative medicament </p> </td> </tr>
<tr class="table-header separated">
<td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Outcomes</b> </p> </td> <td align="" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Relative effect<br> (95% CI)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Number of Participants<br> (studies)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Quality of the evidence<br> (GRADE)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Comments</b> </p> </td> </tr>
<tr class="table-header separated">
<td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Assumed risk</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Corresponding risk</b> </p> </td> </tr>
<tr class="table-header separated">
<td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Control</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Experimental</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Endoflas versus ZOE</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Clinical failure (6 months)</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>128 per 1000</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>33.3 per 1000 (6.4 per 1000 to 192 per 1000)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>RR 0.26 (0.05 to 1.50)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>80 (2 studies)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br><b>moderate</b><sup>1</sup></p> </td> <td align="" valign="" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>One trial assessed failure at 12 months: RR 1.00, 95% 0.07 to 14.55</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Radiological failure (6 months)</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>128 per 1000</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>33.3 per 1000 (6.4 per 1000 to 192 per 1000)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>RR 0.26 (0.05 to 1.50)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>80 (2 studies)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br><b>moderate</b><sup>1</sup></p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Metapex versus ZOE</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Clinical failure (12 months)</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>97 per 1000</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>68.9 per 1000 (14.6 per 1000 to 323 per 1000)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>RR 0.71 (0.15 to 3.33)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>62 (2 studies)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br><b>moderate</b><sup>1</sup></p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Results similar at 6 months</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Radiological failure (12 months)</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>129 per 1000</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>129 per 1000 (40 per 1000 to 421.8 per 1000)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>RR 1.00 (0.31 to 3.27)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>62 (2 studies)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br><b>moderate</b><sup>1</sup></p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Results similar at 6 months</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Other comparisons assessed in more than one trial that had treatment failures</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Clinical failure</b> </p> </td> <td align="" valign="" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>The quality of the evidence was rated as <b>low</b> for 1 comparison: Vitapex versus ZOE (favouring ZOE)<sup>2</sup></p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Radiological failure</b> </p> </td> <td align="" valign="" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>The quality of the evidence was rated as <b>low</b> for 2 comparisons: Vitapex versus ZOE<sup>2</sup> (favouring ZOE); calcium hydroxide versus ZOE<sup>3</sup></p> </td> </tr>
</tbody>
<tfoot><tr>
<td colspan="7"> <div class="table-footnote"> <p><sup>1.</sup> Downgraded 1 level due to imprecision<br><sup>2.</sup> Downgraded 2 levels due to very substantial inconsistency<br><sup>3.</sup> Downgraded 1 level due to substantial inconsistency and 1 level due to imprecision </p> </div> </td> </tr></tfoot>
</table>
</div> <div class="table" id="CD003220-tbl-0003"> <a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading">
<span class="table-label">Summary of findings 3.</span>Â <span class="table-title">Direct pulp capping compared with direct pulp capping using alternative medicament for extensive decay in primary teeth</span>
</div>
<table class="summary-of-findings framed">
<tbody>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Direct pulp capping compared with direct pulp capping using alternative medicament for extensive decay in primary teeth</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Population:</b> children with extensive decay in primary teeth </p> <p><b>Settings:</b> primary care </p> <p><b>Intervention:</b> direct pulp capping with 1 type of medicament </p> <p><b>Comparison:</b> direct pulp capping using alternative medicament </p> </td> </tr>
<tr class="table-header separated">
<td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Outcomes</b> </p> </td> <td align="" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Relative effect<br> (95% CI)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Number of participants<br> (studies)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Quality of the evidence<br> (GRADE)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Comments</b> </p> </td> </tr>
<tr class="table-header separated">
<td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Assumed risk</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Corresponding risk</b> </p> </td> </tr>
<tr class="table-header separated">
<td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Control</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Experimental</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>Seven trials evaluated 22 comparisons of different medicaments for direct pulp capping. Each comparison was assessed by a single trial. </p> <p>There were no clinical or radiological failures in two comparisons: acetoneâbased totalâetch adhesive versus calcium hydroxide; MTA versus calcium hydroxide. </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Clinical failure (at six, 12 and 24 months)</b> </p> </td> <td align="" valign="" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>The quality of the evidence was assessed as <b>low</b> for 5 comparisons<sup>1</sup>: calcium hydroxide versus formocresol (favouring formocrescol), MTA versus 3Mix and MTA versus simvastatin (favouring MTA), 3Mix versus 3Mixtatin and 3Mixtatin versus simvastatin (favouring 3Mixtatin). </p> <p>The quality of the evidence was rated as <b>very low</b> for all other comparisons.<sup>2</sup></p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Radiological failure (at six, 12 and 24 months)</b> </p> </td> <td align="" valign="" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>The quality of the evidence was rated as <b>low</b> for 1 comparison: calcium hydroxide versus formocresol<sup>1</sup> (favouring formocresol). </p> <p>The quality of the evidence was rated as <b>very low</b> for all other comparisons.<sup>2</sup></p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br><b>CI:</b> Confidence interval; <b>RR:</b> risk ratio </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>GRADE Working Group grades of evidence<br><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr>
</tbody>
<tfoot><tr>
<td colspan="7"> <div class="table-footnote"> <p><sup>1.</sup> Downgraded 1 level due to risk of bias and 1 level due to imprecision<br><sup>2.</sup> Downgraded 1 level due to risk of bias and 2 levels due to severe imprecision </p> </div> </td> </tr></tfoot>
</table>
</div> </section></section></body></html></body></html>
